Pediatrix EVP granted shares, tax shares withheld

Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore reported equity transactions in company common stock.

Rhea-AI Filing Summary

Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore reported equity transactions in company common stock. She acquired 39,925 shares on March 1, 2026 as a share award tied to performance conditions from a program established on March 1, 2023.

On the same date, 26,931 shares were withheld to satisfy tax obligations upon vesting of shares at a price of $19.85 per share. After these direct transactions, she held 149,236 shares directly. An additional 52,598 shares are held indirectly through a trust for which she and her spouse serve as trustees.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Moore Mary Ann E

Role EVP, GC, Chief Admin Off & Sec

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	39,925	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	26,931	$19.85	$535K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 149,236 shares (Direct); Common Stock — 52,598 shares (Indirect, By Trust)

Footnotes (3)

1. F1. Represents shares awarded pursuant to the satisfaction of performance conditions per the terms of a performance-based restricted share program established on March 1, 2023.
2. F2. Represents 26,931 shares withheld for payment of taxes upon vesting of shares.
3. F3. The reporting person and her spouse are trustees of the trust that holds the reported securities. The reporting person claims beneficial interest of the reported securities except to the extent of her pecuniary interest therein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transactions did Pediatrix (MD) executive Mary Ann E. Moore report?

Mary Ann E. Moore reported a performance-based stock award and a related tax withholding. She received 39,925 Pediatrix common shares and had 26,931 shares withheld to cover taxes upon vesting, all dated March 1, 2026, according to the Form 4 disclosure.

How many Pediatrix (MD) shares did Mary Ann E. Moore acquire in the latest filing?

She acquired 39,925 Pediatrix common shares as a performance-based award. The award reflects satisfaction of performance conditions under a restricted share program established on March 1, 2023, increasing her directly held equity stake in the company on March 1, 2026.

Why were 26,931 Pediatrix (MD) shares disposed of in Mary Ann E. Moore’s Form 4?

The 26,931 shares were withheld to pay taxes upon vesting of previously granted shares. This tax-withholding disposition, priced at $19.85 per share, is a non-open-market mechanism commonly used to satisfy statutory tax obligations without an ordinary share sale.

What is Mary Ann E. Moore’s Pediatrix (MD) direct share ownership after these transactions?

Following the award and tax withholding, she directly owned 149,236 Pediatrix common shares. This direct holding reflects her equity position after the March 1, 2026 share grant and the related tax-withholding disposition reported in the Form 4 filing.

Does Mary Ann E. Moore have indirect Pediatrix (MD) share ownership through a trust?

Yes. An additional 52,598 Pediatrix common shares are held indirectly in a trust. She and her spouse serve as trustees, and she claims beneficial interest in those securities only to the extent of her pecuniary interest, as described in the Form 4 footnote.

Was the Pediatrix (MD) share disposition by Mary Ann E. Moore an open-market sale?

No. The reported disposition involved 26,931 shares withheld to pay taxes upon vesting. This tax-withholding transaction, coded “F,” reflects delivery of shares for tax liabilities rather than an open-market sale to outside investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 05:00 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moore Mary Ann E

(Last) (First) (Middle)

1301 CONCORD TERRACE

(Street)

SUNRISE FL 33323

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GC, Chief Admin Off & Sec

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A(1)		39,925	A	$0	176,167	D
Common Stock	03/01/2026		F(2)		26,931	D	$19.85	149,236	D
Common Stock								52,598	I	By Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares awarded pursuant to the satisfaction of performance conditions per the terms of a performance-based restricted share program established on March 1, 2023.

2. Represents 26,931 shares withheld for payment of taxes upon vesting of shares.

3. The reporting person and her spouse are trustees of the trust that holds the reported securities. The reporting person claims beneficial interest of the reported securities except to the extent of her pecuniary interest therein.

	/s/ Mary Ann E. Moore, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.